Olgu Sunumu
BibTex RIS Kaynak Göster

A Severe Autoimmune-like Anti-Tuberculosis Drug-induced Liver Injury: Case Report and Review

Yıl 2018, Cilt: 08 Sayı: 03, 128 - 134, 15.09.2018
https://doi.org/10.5799/jmid.458463

Öz

Drug-induced
liver injury is one of the most significant adverse drugs reactions and, in
severe cases, could be a potentially life-threatening condition. It can be
classified in intrinsic and idiosyncratic reactions and, anti-tuberculous drugs
are known to induce the later one. In some cases, it might develop some
autoimmune features which represent a challenge for both diagnosis and
treatment. We report a 37-year-old woman who was admitted to our hospital with
signs of severe acute liver injury. She was diagnosed with autoimmune-like
drug-induced liver injury by anti-tuberculous drugs and was treated with
corticosteroids, N-Acetylcysteine and Ursodesoxycholic acid. Indeed, based on
this case a review of the literature is presented. J Microbiol Infect Dis 2018; 8(3):128-134

Kaynakça

  • 1) Chalasani NP, Hayashi PH, Bonkovsky HI, Navarro VJ, Lee WM, Fontana RJ. ACG clinical guideline: The diagnosis and management of idiosyncratic drug-induced liver injury. The Am J Gastroenterol 2014; 109(7):950-966. 2) Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. J Clin Exp Hepatol 2013;3(1): 37-49. 3) Naqvi IH, Mahmood K, Talib A, Mahmood A. Antituberculosis drug-induced liver injury: an ignored fact, assessment of frequency, patterns, severity and risk factors. Open Journal of Gastroenterology 2015;5(12):173-184. 4) Yu YC, Mao YM, Chen CW, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int 2017; 11(3):221-241. 5) Saukkonen JJ, Cohn DL, Jasmer RM, et al. An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy. Am J Respir Crit Care Med 2006; 174(8):935-952. 6) Altındiş M, Çetinkaya Z, Kalaycı R, Ciftçi IH, Arslan A, Aktepe OC. Detection of Mycobacterium isolates with different methods and their resistance ratios against anti-tuberculosis drugs. J Microbiol Infect Dis 2011; 1 (1): 5-9. 7) Alarcón V, Alarcón E, Figueroa C, Mendoza-Ticona A. Tuberculosis en el Perú: situación epidemiológica, avances y desafíos para su control. Rev Peru Med Exp Salud Publica 2017; 34(2): 299-310. 8) Saithanyamurthi H, Faust AJ. Drug-Induced Liver Disease: Clinical Course. Clin Liver Dis 2017; 21(1):21-34. 9) Giordano C, Rivas J, Zervos X. An update on treatment of drug-induced liver injury. J Clin Transl Hepatol 2014;2(2):74-79. 10) Abbara A, Chitty S, Roe JK, et al. Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK. BMC Infect Dis 2017; 17(1):231. 11) Jong E, Conradie F, Berhanu R, et al. Consensus statement: Management of drug-induced liver injury in HIV-positive patients treated for TB. South Afr J HIV Med 2013; 14(3): 113-119. 12) Pozniak A, Bracchi M, Awosusi F, et al. British HIV Association guidelines for the management of TB/HIV co-infection in adults, 2017 [Internet]. Bhiva.org. 2018 [cited 1 May 2018]. Available from: http://www.bhiva.org/documents/Guidelines/TB/BHIVA-TB-HIV-co-infection-guidelines-consultation.pdf 13) Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63(7):147-195. 14) deLemos AS, Foureau DM, Jacobs C, Ahrens W, Russo MW, Bonkovsky HL. Drug-induced liver injury with autoimmune features. Semin Liver Dis 2014; 34(2):194-204. 15) Rangel MA, Pinto I, Duarte R, Carvalho I. Antituberculosis Drug-Induced Liver Injury with Autoimmune Features: Facing Diagnostic and Treatment Challenges. Case Rep Pediatr 2017; 2017:5741896. 16) Stine JG, Lewis JH. Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review Expert Rev Gastroenterol Hepatol 2016; 10(4):517-536. 17) Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-Acetylcysteine improves transplant free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009; 137(3):856-64. 18) Nabi T, Nabi S, Rafiq N, Shah A. Role of N-acetylcysteine treatment in non-acetaminophen-induced acute liver failure: A prospective study. Saudi J Gastroenterol 2017; 23(3):169-175. 19) Darweesh SK, Ibrahim MF, El-Tahawy MA. Effect of N-acetylcysteine on mortality and liver transplantation rate in non-acetaminophen-induced acute liver failure: A multicenter study. Clin Drug Investig 2017; 37(5):473-482. 20) Hu J, Zhang Q, Ren X, Sun Z, Quan Q. Efficacy and safety of acetylcysteine in "non-acetaminophen" acute liver failure: A meta-analysis of prospective clinical trials. Clin Res Hepatol Gastroenterol 2015; 39(5):594-599. 21) Hu PF, Wang PQ, Chen H, et al. Beneficial effect of corticosteroids for patients with severe drug-induced liver injury. J Dig Dis 2016; 17(9):618-627. 22) Wree A, Dechêne A, Herzer K, et al. Steroid and ursodesoxycholic acid combination therapy in severe drug-induced liver injury. Digestion 2011; 84(1):54-59.
Yıl 2018, Cilt: 08 Sayı: 03, 128 - 134, 15.09.2018
https://doi.org/10.5799/jmid.458463

Öz

Kaynakça

  • 1) Chalasani NP, Hayashi PH, Bonkovsky HI, Navarro VJ, Lee WM, Fontana RJ. ACG clinical guideline: The diagnosis and management of idiosyncratic drug-induced liver injury. The Am J Gastroenterol 2014; 109(7):950-966. 2) Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. J Clin Exp Hepatol 2013;3(1): 37-49. 3) Naqvi IH, Mahmood K, Talib A, Mahmood A. Antituberculosis drug-induced liver injury: an ignored fact, assessment of frequency, patterns, severity and risk factors. Open Journal of Gastroenterology 2015;5(12):173-184. 4) Yu YC, Mao YM, Chen CW, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int 2017; 11(3):221-241. 5) Saukkonen JJ, Cohn DL, Jasmer RM, et al. An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy. Am J Respir Crit Care Med 2006; 174(8):935-952. 6) Altındiş M, Çetinkaya Z, Kalaycı R, Ciftçi IH, Arslan A, Aktepe OC. Detection of Mycobacterium isolates with different methods and their resistance ratios against anti-tuberculosis drugs. J Microbiol Infect Dis 2011; 1 (1): 5-9. 7) Alarcón V, Alarcón E, Figueroa C, Mendoza-Ticona A. Tuberculosis en el Perú: situación epidemiológica, avances y desafíos para su control. Rev Peru Med Exp Salud Publica 2017; 34(2): 299-310. 8) Saithanyamurthi H, Faust AJ. Drug-Induced Liver Disease: Clinical Course. Clin Liver Dis 2017; 21(1):21-34. 9) Giordano C, Rivas J, Zervos X. An update on treatment of drug-induced liver injury. J Clin Transl Hepatol 2014;2(2):74-79. 10) Abbara A, Chitty S, Roe JK, et al. Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK. BMC Infect Dis 2017; 17(1):231. 11) Jong E, Conradie F, Berhanu R, et al. Consensus statement: Management of drug-induced liver injury in HIV-positive patients treated for TB. South Afr J HIV Med 2013; 14(3): 113-119. 12) Pozniak A, Bracchi M, Awosusi F, et al. British HIV Association guidelines for the management of TB/HIV co-infection in adults, 2017 [Internet]. Bhiva.org. 2018 [cited 1 May 2018]. Available from: http://www.bhiva.org/documents/Guidelines/TB/BHIVA-TB-HIV-co-infection-guidelines-consultation.pdf 13) Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63(7):147-195. 14) deLemos AS, Foureau DM, Jacobs C, Ahrens W, Russo MW, Bonkovsky HL. Drug-induced liver injury with autoimmune features. Semin Liver Dis 2014; 34(2):194-204. 15) Rangel MA, Pinto I, Duarte R, Carvalho I. Antituberculosis Drug-Induced Liver Injury with Autoimmune Features: Facing Diagnostic and Treatment Challenges. Case Rep Pediatr 2017; 2017:5741896. 16) Stine JG, Lewis JH. Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review Expert Rev Gastroenterol Hepatol 2016; 10(4):517-536. 17) Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-Acetylcysteine improves transplant free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009; 137(3):856-64. 18) Nabi T, Nabi S, Rafiq N, Shah A. Role of N-acetylcysteine treatment in non-acetaminophen-induced acute liver failure: A prospective study. Saudi J Gastroenterol 2017; 23(3):169-175. 19) Darweesh SK, Ibrahim MF, El-Tahawy MA. Effect of N-acetylcysteine on mortality and liver transplantation rate in non-acetaminophen-induced acute liver failure: A multicenter study. Clin Drug Investig 2017; 37(5):473-482. 20) Hu J, Zhang Q, Ren X, Sun Z, Quan Q. Efficacy and safety of acetylcysteine in "non-acetaminophen" acute liver failure: A meta-analysis of prospective clinical trials. Clin Res Hepatol Gastroenterol 2015; 39(5):594-599. 21) Hu PF, Wang PQ, Chen H, et al. Beneficial effect of corticosteroids for patients with severe drug-induced liver injury. J Dig Dis 2016; 17(9):618-627. 22) Wree A, Dechêne A, Herzer K, et al. Steroid and ursodesoxycholic acid combination therapy in severe drug-induced liver injury. Digestion 2011; 84(1):54-59.
Toplam 1 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Bölüm Olgu Sunumu
Yazarlar

Jorge R. Mosqueira Bu kişi benim

Sue Anicama Bu kişi benim

Jorge De Los Ríos Bu kişi benim

Yayımlanma Tarihi 15 Eylül 2018
Yayımlandığı Sayı Yıl 2018 Cilt: 08 Sayı: 03

Kaynak Göster

APA Mosqueira, J. R., Anicama, S., & De Los Ríos, J. (2018). A Severe Autoimmune-like Anti-Tuberculosis Drug-induced Liver Injury: Case Report and Review. Journal of Microbiology and Infectious Diseases, 08(03), 128-134. https://doi.org/10.5799/jmid.458463
AMA Mosqueira JR, Anicama S, De Los Ríos J. A Severe Autoimmune-like Anti-Tuberculosis Drug-induced Liver Injury: Case Report and Review. J Microbil Infect Dis. Eylül 2018;08(03):128-134. doi:10.5799/jmid.458463
Chicago Mosqueira, Jorge R., Sue Anicama, ve Jorge De Los Ríos. “A Severe Autoimmune-Like Anti-Tuberculosis Drug-Induced Liver Injury: Case Report and Review”. Journal of Microbiology and Infectious Diseases 08, sy. 03 (Eylül 2018): 128-34. https://doi.org/10.5799/jmid.458463.
EndNote Mosqueira JR, Anicama S, De Los Ríos J (01 Eylül 2018) A Severe Autoimmune-like Anti-Tuberculosis Drug-induced Liver Injury: Case Report and Review. Journal of Microbiology and Infectious Diseases 08 03 128–134.
IEEE J. R. Mosqueira, S. Anicama, ve J. De Los Ríos, “A Severe Autoimmune-like Anti-Tuberculosis Drug-induced Liver Injury: Case Report and Review”, J Microbil Infect Dis, c. 08, sy. 03, ss. 128–134, 2018, doi: 10.5799/jmid.458463.
ISNAD Mosqueira, Jorge R. vd. “A Severe Autoimmune-Like Anti-Tuberculosis Drug-Induced Liver Injury: Case Report and Review”. Journal of Microbiology and Infectious Diseases 08/03 (Eylül 2018), 128-134. https://doi.org/10.5799/jmid.458463.
JAMA Mosqueira JR, Anicama S, De Los Ríos J. A Severe Autoimmune-like Anti-Tuberculosis Drug-induced Liver Injury: Case Report and Review. J Microbil Infect Dis. 2018;08:128–134.
MLA Mosqueira, Jorge R. vd. “A Severe Autoimmune-Like Anti-Tuberculosis Drug-Induced Liver Injury: Case Report and Review”. Journal of Microbiology and Infectious Diseases, c. 08, sy. 03, 2018, ss. 128-34, doi:10.5799/jmid.458463.
Vancouver Mosqueira JR, Anicama S, De Los Ríos J. A Severe Autoimmune-like Anti-Tuberculosis Drug-induced Liver Injury: Case Report and Review. J Microbil Infect Dis. 2018;08(03):128-34.